The observational study presented at the 2026 ATS International Conference, analyzing over 146,900 COPD and 194,900 pneumonia encounters across matched U.S. hospitals, reveals statistically significant deteriorations post-acquisition: a 1-percentage-point rise in 30-day COPD readmissions and nearly 1-point increase in pneumonia in-hospital mortality. This large-scale matched cohort design, while not an RCT, controls for key confounders and highlights patterns missed in prior broad adverse-event reports. Beyond the source's emphasis on profit incentives, the findings connect to a documented wave of private equity hospital roll-ups since 2010, where short-term return horizons (typically 3-7 years) drive staffing reductions and protocol shortcuts, as evidenced by a 2022 JAMA Internal Medicine analysis of 204 PE-acquired facilities showing elevated bloodstream infections. Original coverage underplays how these dynamics compound for respiratory patients, who often require nuanced, time-intensive interventions vulnerable to lean-staffing models. Cross-referencing with a 2023 Health Affairs study on Medicare beneficiaries further exposes the pattern: PE-owned sites exhibited 5-8% higher readmission rates across chronic conditions, underscoring that pulmonary declines are not isolated but symptomatic of degraded care quality under leveraged buyouts. Conflicts of interest remain low here, with academic authors from Beth Israel Deaconess, yet broader PE research frequently faces funding opacity from industry ties.